Pharmaceuticals company Windlas Biotech announced Q2FY27 results Financial Highlights: Revenue from Operations: In Q2FY27, revenue from operations stood at Rs 2,639.08 million, increasing by 6.37% QoQ from Rs 2,480.99 million in Q1FY27 and 18.66% YoY from Rs 2,223.98 million in Q2FY26. For H1FY27, revenue from operations grew by 18.39% YoY to Rs 5,120.07 million compared to Rs 4,324.88 million in H1FY26. Total Income: In Q2FY27, total income reached Rs 2,677.69 million, rising 5.75% QoQ from Rs 2,532.12 million in Q1FY27 and 18.46% YoY from Rs 2,260.43 million in Q2FY26. For H1FY27, total income rose by 18.04% YoY to Rs 5,209.81 million against Rs 4,413.72 million in H1FY26. Profit Before Tax (PBT): In Q2FY27, PBT stood at Rs 233.00 million, up 1.59% QoQ from Rs 229.36 million in Q1FY27 and down 1.22% YoY from Rs 235.88 million in Q2FY26. For H1FY27, PBT was Rs 462.36 million, reflecting a 1.30% YoY decrease compared to Rs 468.46 million in H1FY26. Profit After Tax (PAT): In Q2FY27, PAT reached Rs 180.52 million, growing 2.26% QoQ from Rs 176.53 million in Q1FY27 and 1.42% YoY from Rs 178.00 million in Q2FY26. For H1FY27, PAT increased by 0.68% YoY to Rs 357.05 million from Rs 354.65 million in H1FY26. Earnings Per Share (EPS - Basic & Diluted): In Q2FY27, basic EPS stood at Rs 8.75 (up 3.43% QoQ from Rs 8.46 in Q1FY27 and 3.18% YoY from Rs 8.48 in Q2FY26), while diluted EPS stood at Rs 8.56 (up 2.88% QoQ from Rs 8.32 in Q1FY27 and 1.90% YoY from Rs 8.40 in Q2FY26). For H1FY27, basic EPS increased by 1.77% YoY to Rs 17.21 (from Rs 16.91 in H1FY26) and diluted EPS rose by 0.72% YoY to Rs 16.84 (from Rs 16.72 in H1FY26). Hitesh Windlass, Chairman & Managing Director, Windlas Biotech, said: “The Indian Pharmaceutical Market (IPM) reported volume growth of 2.3% during the quarter. Windlas Biotech is extending its track record to 15 consecutive quarters of record revenue with 19% YoY growth to Rs 264 crore. Each of our three businesses plays a distinct role in our growth story. Generic Formulations CDMO remains our anchor: customers have entrusted us with a larger share of their portfolios and new products, which lifted Q2FY27 revenue by 34% to Rs 264 crore and H1FY27 revenue by 32% to Rs 422 crore. In Trade Generics & Institutional, we have used this period to reshape the portfolio, replacing codeine-based products with new launches that give the business a broader and more resilient base. This vertical generated revenue Rs 36 crore in Q2FY27 and Rs 66 crore in H1FY27. Export markets have longer lead times. We continue to focus on investments in dossiers, product registrations and site approvals, with few turning into commercial supplies, resulting in Q2FY27 revenue growth of 26% to Rs 12 crore and H1FY27 revenue growth of 46% to Rs 23 crore. Together, these give us a deeper customer base, a stronger portfolio and a growing geographical presence. We remain committed to creating long-term value for our shareholders. The company reported its highest-ever earnings per share (EPS) of Rs 17.21 in H1FY27. In line with our dividend policy and commitment to shareholder returns, the company paid a dividend of Rs 13 crore (Rs 6.3 per share) related to FY26. With the Rs 47 crore buyback successfully completed without promoter participation, the dividend paid and capex funded from our own resources, we closed the half-year with healthy net liquidity of Rs 223 crore, a balance sheet that supports both shareholder returns and growth. The opportunities ahead of us are significant, and we approach them with confidence, humility, and determination. Backed by a dedicated team and the commitment to excellence, we are focused on building a stronger Windlas Biotech that creates lasting value for patients, partners, employees and shareholders alike.” Komal Gupta, CEO & CFO, Windlas Biotech, said: “Consistency is not the most exciting word in business, but it is the one our customers & shareholders value the most. In H1FY27, Windlas crossed Rs 500 crore in half-yearly revenue for the first time. Revenue grew 19% YoY to Rs 264 crore in Q2FY27 and 18% to Rs 512 crore in H1FY27. For our customers, this consistency matters as much as our capacity, because it shows them that Windlas can grow alongside them. Sustaining that confidence, quarter after quarter, remains our first priority. We remain as focused on the quality of our earnings as on the pace of our growth. Excluding non-cash ESOP expenses, EBITDA for Q2FY27 was Rs 36 crore (13.7%) and PAT Rs 25 crore (9.5%), while H1FY27 EBITDA stood at Rs 70 crore (13.7%) and PAT Rs 50 crore (9.7%). On a reported basis, EBITDA and PAT were Rs 29 crore and Rs 18 crore for the quarter, and Rs 56 crore and Rs 36 crore for the half-year. We delivered this while continuing to invest in capacity and capability, which reflects the operating discipline that allows us to fund our future from the strength of our present. In line with our long-term growth aspirations, the commercialisation of Plant-6 in September 2026 marks a key addition to our manufacturing infrastructure. During Q2FY27, Plant-4 and Plant-5 (Injectable Facility) received EU GMP certification in line with our long-term export strategy. Our earlier investments in the P-2 extension and injectables facility continue to progress steadily. Our focus on capital efficiency is reflected in ROCE and ROE at 28% and 24%, respectively, despite Plant 6 Capex. Windlas is well positioned to respond to evolving industry dynamics and capitalise on emerging opportunities. We remain confident in the strength of our fundamentals and our ability to create enduring value for all stakeholders.” Result PDF